Swiss researchers have studied the three-dimensional structure of "cubosomes," which are naturally occurring collections of cube-shaped fat molecules; and with that new knowledge, they have inched closer to using these capsules to deliver drugs and nutrients.
Ann Arbor, MI's RetroSense Therapeutics announced a $6 million Series B funding round to fund a Phase I/II study of its gene therapy candidate for vision restoration, as well as a "a second promising gene therapy candidate." The financing brings its total haul to $13 million, including a $7 million Series A round completed earlier this year.
Experiments show that zinc oxide nanopyramids have the potential to become an antibacterial coating for implants like artificial joints, researchers at the University of Michigan say. Zinc oxide is a common ingredient in sunscreen, but in order to work as an effective antibiotic when placed on an implant, the team needed to modify their drug delivery.
Dr. Todd Mainprize of Toronto's Sunnybrook Hospital says he has accomplished something that has never been done before: open the blood-brain barrier using focused ultrasound, an achievement that enables treatment of a variety of neurological conditions.
Researchers at UCLA's California NanoSystems Institute have developed a nanoparticle delivery system that improves an antibiotic's ability to combat the bacteria Francisella tularensis.
Johnson & Johnson's Janssen announced that a Phase IIb study of a combination regimen of two investigational long-acting injectable HIV drugs found that the therapy performed similarly to a regimen consisting of three oral medications.
Researchers from the University at Buffalo in New York have won an award from the National Science Foundation to study the way ebolavirus enters cells, potentially shedding light on delivery methods for treatment of the infection.
GlaxoSmithKline secured FDA approval for Nucala, an injectable treatment for asthma, a therapeutic dominated by inhaled drugs. Still, the alternative form of drug delivery for respiratory conditions has the potential to reach sales of $7 billion a year, according to analysts.
A survey of more than physicians found that 31% think opioid antagonists is the abuse-deterrent formulation that is most needed to combat the opioid abuse epidemic--an issue that's been implicated in the startling rise of the death rate of middle-aged white Americans without a college degree.
Amgen's Imlygic became the first genetically modified oncolytic viral therapy to earn FDA approval.
Everolimus has eclipsed paclitaxcel as the drug of choice in drug-eluting stents, which are a definitive advance over bare metal stents. But is that the optimal drug for the new class of stents? Perhaps the right choice is under development by nonprofit contract research organization CBSET of Lexington, MA. They're testing a sirolimus analog called corolimus.
Cardiac arrhythmia is the result of a specific kind of cell's presence in the heart that causes the organ to beat irregularly. And researchers from the University of Michigan have developed a nanoparticle that can target and destroy those cells without doing harm to the healthy cells in the heart.
Scientists from Oregon State University have developed a nanoparticle potentially capable of targeting and destroying tough-to-reach tumor cells left behind after surgery for ovarian cancer.
The first subject in a Phase I study of Pfizer's subcutaneous sickle cell anemia candidate has been dosed, triggering $1 million milestone payment to Halozyme, developer of the enhanze drug delivery platform.
Novartis announced FDA approval last week of its Utibron Neohaler as a long-term maintenance treatment for COPD via the delivery of the bronchodilating agents indacaterol and glycopyrrolate.
Researchers from MIT--including drug delivery maven Robert Langer--and Massachusetts General Hospital have found a quick way to deliver drugs to the gastrointestinal tract using ultrasound, someday improving treatment of disorders there such as inflammatory bowel disease, ulcerative colitis and Crohn's disease.
Cleveland Clinic's investigational convection-enhanced catheter for the delivery of drugs directly into the brain showed promise in first-in-human clinical trials of brain cancer patients.
To treat many neurological diseases, drugs must first pass the blood-brain barrier. But that barrier has formed around the brain to block dangerous substances and, in turn, it thwarts about 98% of drugs, according to a group of Boston scientists. That team has since developed a technique to make crossing the blood-brain barrier less of a hindrance.
Endo and BioDelivery Sciences International announced FDA approval of Belbuca, the first and only polymer strip for the delivery of the painkiller buprenorphine from the inside of the cheek.
Capsugel announced the launch of its enTRinsic drug delivery platform to provide enteric protection and rapid release of oral drugs in the upper gastrointestinal tract without the use of a functional coating.